Vir Biotechnology, Inc. (VIR)

Vir Biotechnology's stock (VIR) has seen an upward trend, increasing by 63.79% in the past six months. Key events influencing this performance include a global strategic collaboration with Astellas to advance VIR-5500 for prostate cancer, positive updated Phase 1 data for VIR-5500 monotherapy, a corporate update and financial results for the fourth quarter and full year 2025, a proposed public offering of common stock, a licensing agreement with Norgine Pharma UK Limited for the combination of tobevibart and elebsiran, and the announcement that Executive Vice President and Chief Medical Officer, Mark Eisner, would step down effective April 24, 2026.

As a clinical-stage biopharmaceutical company, Vir Biotechnology's primary revenue streams currently come from licensing rights and grants, rather than direct sales of commercialized products. Therefore, traditional demand seasonality is not a significant factor for its current business model. The demand for its future products will largely depend on clinical trial success, regulatory approvals, and market adoption upon commercialization.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutic products for serious infectious diseases and cancer. The company's pipeline includes investigational therapies targeting chronic hepatitis delta virus (CHD) and various solid tumors, utilizing the PRO-XTEN® dual-masked T-cell engager (TCE) platform. Key product candidates include VIR-5500, VIR-5818, and VIR-5525 for solid tumors, and a combination of tobevibart and elebsiran for chronic hepatitis delta. Additionally, Vir Biotechnology has preclinical candidates aimed at influenza A and B antibodies, antibody-drug conjugates, and coronavirus monoclonal antibodies. The company's revenue is primarily generated through licensing rights and grants.

Vir Biotechnology's global headquarters are located in San Francisco, California, United States. The company also maintains research activities in Bellinzona, Switzerland. As part of strategic cost optimization efforts, Vir Biotechnology closed its research and development facilities in St. Louis, Missouri, and Portland, Oregon, in 2024.

Vir Biotechnology's brand reputation has been positively influenced by advancements in its clinical pipeline and strategic collaborations. The positive updated Phase 1 data for VIR-5500 and the global strategic collaboration with Astellas have been highlighted as significant achievements. The licensing agreement with Norgine for its hepatitis delta treatment also contributes to a positive perception of the company's progress and potential. Vir Biotechnology was recognized as the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500 list, indicating a strong track record of rapid development and impact.

Vir Biotechnology has a diverse ownership structure. Institutional investors hold a significant portion of the company's stock, with approximately 60.01% (or 41.40% depending on the source) of shares held by institutions. Major institutional owners include BlackRock, Inc., SB Investment Advisers (uk) Ltd, Arch Venture Corp, Vanguard Group Inc, Glaxosmithkline Plc, State Street Corp, Fmr Llc, Morgan Stanley, Dimensional Fund Advisors Lp, and Orbimed Advisors Llc. Insiders hold around 10.72% of the stock, while public companies and individual investors account for approximately 29.26% (or 18.62%). SVF Endurance (Cayman) Ltd is noted as owning the most shares of Vir Biotechnology.